Elusys Therapeutics, Inc.
about us Elusys & Biodefense product news&events careers
Elusys Overview Leadership
Executive Team Board of  Directors
Anthrax & Bioterrorism Contract Experience Useful Links
Anthim Anthrax Antibody Anthim Publication
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2012

view archives

 

September 13, 2012

Elusys awarded additional $14.5 million under existing U.S. government contracts supporting expanded human safety studies of ETI-204 for treatment of inhalational anthrax

 

August 3, 2012

 

Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin

 
August 1, 2012

Elusys awarded additional $50.2 million under an existing U.S. government contract to support final stages of development of ETI-204, for treatment of inhalational Anthrax

 

 

 

 

 

 

 

 

  • Copyright© 2013 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers